DUBLIN — April 2, 2020 — Horizon Therapeutics plc (Nasdaq: HZNP) announced today that it has acquired Curzion Pharmaceuticals, Inc., a privately held development-stage biopharma company, and its development-stage oral...
TargeGen initiates Phase II clinical trial of topically-applied drug for age-related macular degeneration
News | 07. 30. 2007
TargeGen
TargeGen, Inc. today announced that the Company has initiated a multi-center Phase II clinical trial of topically applied TG100801 in patients with age-related macular degeneration (AMD).
